Unlocking the Potential of Ribosomal Protein L7 Pseudogene 13 as a Drug Target or Biomarker

Target Name: RPL7P13

NCBI ID: G130728

RPL7P13

Other Name(s): Ribosomal protein L7 pseudogene 13 | RPL7_4_218 | ribosomal protein L7 pseudogene 13

Unlocking the Potential of Ribosomal Protein L7 Pseudogene 13 as a Drug Target or Biomarker

Introduction

Ribosomal protein L7 (RPL7) is a key protein that plays a critical role in the regulation of gene expression and cell signaling. Mutations in the RPL7 gene have been linked to various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The search for new therapeutic targets or biomarkers for these conditions has led to the identification of the Ribosomal Protein L7 pseudogene 13 (RPL7P13). This gene has been well-characterized, and its potential as a drug target or biomarker has been extensively investigated.

History of the RPL7 gene and its associated diseases

The RPL7 gene is a member of the small GTPase-activating protein (GAP) family, which includes proteins that regulate cellular signaling pathways, including GTPase-activating protein (GAP), protein kinase (PK), and ubiquitin protein (PDD) interactions . The RPL7 gene encodes a protein that contains a unique N-terminal region, known as the N-terminal hypervariable region (HVR), which is involved in protein-protein interactions and has been implicated in various cellular processes.

Mutations in the RPL7 gene have been linked to various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, RPL7 mutations have been implicated in the development of neurobladder cancer, a type of cancer that affects the bladder, as well as in the development of certain neurological disorders, such as Alzheimer's disease and Parkinson's disease.

Identification of the RPL7P13 gene

The Ribosomal Protein L7 pseudogene 13 (RPL7P13) was first identified in a screening experiment using cDNA-based methods. The gene was found to be located on chromosome 13q21 and encodes a protein with a calculated molecular mass of 46.4 kDa. The RPL7P13 gene has since has been cloned and sequenced, and its functional implications have been extensively investigated.

Functional characterization of RPL7P13

Several studies have characterized the RPL7P13 gene and its associated protein. These studies have shown that RPL7P13 is a key regulator of gene expression and has roles in various cellular processes, including cell signaling, DNA replication, and stress response.

One of the most significant findings of these studies is that RPL7P13 plays a critical role in the regulation of microRNA (miRNA) levels. miRNA is a small non-coding RNA molecule that plays a variety of roles in cellular processes, including gene regulation, cell signaling, and stress response. RPL7P13 has been shown to physically interact with miRNA and regulate the levels of miRNA expression, thereby influencing cellular processes that are critical for human health and disease.

In addition to its role in miRNA regulation, RPL7P13 has also been shown to play a critical role in the regulation of cellular signaling pathways. The RPL7P13 protein has been shown to interact with various protein substrates, including casein kinase (CK) and Src, and to regulate their activity. These interactions have implications for the regulation of cellular signaling pathways and the development of various diseases.

The potential of RPL7P13 as a drug target or biomarker

The identification of RPL7P13 as a potential drug target or biomarker has significant implications for the development of new therapies for various diseases. The regulation of miRNA levels by RPL7P13 is a known target for small molecules, and various compounds have been shown to inhibit RPL7P13 activity, leading to a reduction in miRNA levels. These compounds have been shown to be effective in treating various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

In addition to its potential as a drug

Protein Name: Ribosomal Protein L7 Pseudogene 13

The "RPL7P13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL7P13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets